Skip to Content

Risankizumab Downregulates IL-23-Induced Mucosal Pathogenic Th17 Cells in Patients with Crohn’s Disease

This study, presented by Daniele Noviello, a gastroenterologist and PhD student at the University of Milan, focuses on the impact of different biological therapies on a subset of Th17 cells, known as pathogenic Th17 (pTh17) cells, in patients with Crohn’s disease. The research demonstrates that Risankizumab, unlike Ustekinumab or Vedolizumab, effectively downregulates IL-23-induced mucosal pTh17 cells in these patients.

Daniele Noviello

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top